(Dusigitumab)Biosimilar Reference Antibody-GS40199 新品

货号：GS40199

Dusigitumab (MEDI 573) is a human IgG2λ monoclonal antibody developed as a targeted therapy for cancer. It is designed to neutralize the insulin-like growth factor (IGF) pathway by specifically binding to and inhibiting both IGF2 (Insulin-like Growth Factor 2) and IGF1 (Insulin-like Growth Factor 1). This dual-neutralization aims to block the activation of the IGF-1 receptor (IGF-1R) signaling axis, a key driver of tumor growth, survival, and resistance to therapy in various solid tumors. Clinical trials have evaluated its potential in malignancies where the IGF pathway is implicated, such as hepatocellular carcinoma and other advanced solid tumors.